Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

globe_newswire · 2026-08-20

All patients enrolled and treated across original and FDA-cleared expansion cohorts

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。